The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Quizartinib recommended for approval in the EU
On September 15, 2023, quizartinib, an oral, highly potent and selective type II FLT3 inhibitor previously covered by the AML Hub, was recommended for approval in the European Union (EU) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the treatment of patients with newly diagnosed (ND) acute myeloid leukemia (AML) with FLT3-internal tandem duplication (FLT3-ITD) mutations in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib as a maintenance monotherapy.1 Quizartinib was also recently approved in the US and in Japan for the same indication.
This positive opinion is based on results from the phase III QuANTUM-First trial (NCT02668653), which were previously reported by the AML Hub.1 Quizartinib, in combination with standard chemotherapy, was associated with improved overall survival versus standard chemotherapy alone in patients with ND FLT3-ITD mutated AML.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
